Skip to main content

Advertisement

SpringerLink
Log in

Germline mutations in RAD51C in Jewish high cancer risk families

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Germline mutations in BRCA1 and BRCA2 account for ~30 % of inherited breast cancer. RAD51C was reported as an additional breast/ovarian cancer susceptibility gene in some populations. There is a paucity of data on the putative contribution of this gene to inherited breast/ovarian cancer in Jewish high risk families. High risk Jewish women, none of whom was a carrier of the predominant Jewish mutations in BRCA1 or BRCA2, were screened for RAD51C germline mutations by direct sequencing of exons and flanking intronic sequences. Overall, 206 high risk women, 79 (38.3 %) of Ashkenazi origin, were genotyped for RAD51C mutations: 190 (92.3 %) with uni- or bilateral breast cancer (mean age at diagnosis 51.3 ± 11.1 years), 14 with ovarian cancer (mean age at diagnosis 55.6 ± 8.7 years), and two with both breast and ovarian cancer. No truncating mutations were noted, and two previously described missense mutations were detected: p.Ile144Thr and p.Thr287Ala in Iraqi and mixed ethnicity Balkan-North African participants, respectively. These missense mutations were evolutionarily conserved, possibly pathogenic, based on some prediction algorithms, and were not detected in any of healthy Iraqi (n = 60) and mixed ethnicity (n = 140), cancer free controls, respectively. Germline mutations in RAD51C contribute marginally to breast and ovarian cancer susceptibility in ethnically diverse, Jewish high risk families. The p.Thr287Ala missense mutation may be a recurring, pathogenic RAD51C mutation in ethnically diverse populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130

    Article  PubMed  CAS  Google Scholar 

  2. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308

    Article  Google Scholar 

  3. Irving M, Elmslie F, Berg J (2002) Genetics of breast cancer. Int J Clin Pract 56:677–682

    PubMed  CAS  Google Scholar 

  4. Thompson D, Easton D (2004) The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 9:221–236

    Article  PubMed  Google Scholar 

  5. Somyajit K, Subramanya S, Nagaraju G (2012) Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility. J Biol Chem 287(5):3366–3380

    Article  PubMed  CAS  Google Scholar 

  6. Smeenk G, de Groot AJ, Romeijn RJ, van Buul PP, Zdzienicka MZ, Mullenders LH, Pastink A, Godthelp BC (2012) Rad51C is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability. Mutat Res 689(1–2):50–58

    Google Scholar 

  7. Somyajit K, Subramanya S, Nagaraju G (2010) RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis 31(12):2031–2038

    Article  PubMed  CAS  Google Scholar 

  8. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42:406–409

    Article  PubMed  CAS  Google Scholar 

  9. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Müller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42(5):410–414

    Article  PubMed  CAS  Google Scholar 

  10. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20(16):3278–3288

    Article  PubMed  CAS  Google Scholar 

  11. Vuorela M, Pylkäs K, Hartikainen JM, Sundfeldt K, Lindblom A, von Wachenfeldt Wäppling A, Haanpää M, Puistola U, Rosengren A, Anttila M, Kosma VM, Mannermaa A, Winqvist R (2011) Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat 130(3):1003–1010

    Article  PubMed  CAS  Google Scholar 

  12. Coulet F, Fajac A, Colas C, Eyries M, Dion-Minière A, Rouzier R, Uzan S, Lefranc JP, Carbonnel M, Cornelis F, Cortez A, Soubrier F (2012) Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet. doi:10.1111/j.1399-0004.2012.01917.x

  13. Osorio A, Endt D, Fernández F, Eirich K, de la Hoya M, Schmutzler R, Caldés T, Meindl A, Schindler D, Benitez J (2012) Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet 21(13):2889–2898

    Article  PubMed  CAS  Google Scholar 

  14. Romero A, Pérez-Segura P, Tosar A, García-Saenz JA, Díaz-Rubio E, Caldés T, de la Hoya M (2011) A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat 129(3):939–946

    Article  PubMed  CAS  Google Scholar 

  15. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ (2011) BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 127(3):853–859

    Article  PubMed  CAS  Google Scholar 

  16. Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, kConFab, Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA, Campbell IG (2012) Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat 33(1):95–99

    Article  PubMed  CAS  Google Scholar 

  17. Pang Z, Yao L, Zhang J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y (2011) RAD51C germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat 129(3):1019–1020

    Article  PubMed  Google Scholar 

  18. Lu W, Wang X, Lin H, Lindor NM, Couch FJ (2012) Mutation screening of RAD51C in high-risk breast and ovarian cancer families. Fam Cancer. [Epub Ahead of Print]

  19. Clague J, Wilhoite G, Adamson A, Bailis A, Weitzel JN, Neuhausen SL (2011) RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS One 6(9):e25632

    Article  PubMed  CAS  Google Scholar 

  20. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI (2010) Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 124(3):857–861

    Article  PubMed  CAS  Google Scholar 

  21. De Leeneer K, Van Bockstal M, De Brouwer S, Swietek N, Schietecatte P, Sabbaghian N, Van den Ende J, Willocx S, Storm K, Blaumeiser B, Van Asperen CJ, Wijnen JT, Leunen K, Legius E, Michils G, Matthijs G, Blok MJ, Gomez-Garcia E, De Paepe A, Tischkowitz M, Poppe B, Claes K (2012) Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. Breast Cancer Res Treat 133(1):393–398

    Article  PubMed  CAS  Google Scholar 

  22. Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, Narod SA (2010) RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res 12(4):404

    Article  PubMed  Google Scholar 

  23. Rohlfs EM, Learning WG, Friedman KJ, Couch FJ, Weber BL, Silverman LM (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43:24–29

    PubMed  CAS  Google Scholar 

  24. Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M, Gershoni-Baruch R, Goldberg H, Kaufman B, Ben-Baruch N, Zidan J, Maray T, Soussan-Gutman L, Friedman E (2011) Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat 127(2):489–495

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank all individuals who participated to this study. This study was partially funded by the Israel Cancer Association. This work was done in partial fulfillment of the requirements for a Masters degree for Anya Kushnir at the Department of Human Genetics and Molecular Biology at the Tel-Aviv University, Tel-Aviv, Israel.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. The Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel-Aviv University, 52621, Tel-Hashomer, Tel-Aviv, Israel

    Anya Kushnir, Yael Laitman & Eitan Friedman

  2. The Oncology Institute, Chaim Sheba Medical Center, Tel-Aviv University, Tel-Aviv, Israel

    Shani Paluch Shimon & Raanan Berger

  3. The Sackler School of Medicine, Tel-Aviv University, Tel-Hashomer, Tel-Aviv, Israel

    Raanan Berger & Eitan Friedman

Authors
  1. Anya Kushnir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yael Laitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shani Paluch Shimon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raanan Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eitan Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eitan Friedman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kushnir, A., Laitman, Y., Shimon, S.P. et al. Germline mutations in RAD51C in Jewish high cancer risk families. Breast Cancer Res Treat 136, 869–874 (2012). https://doi.org/10.1007/s10549-012-2317-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-2317-9

Keywords

Search

Navigation